186412-62-4

Usage

Chemical structure

Piperazine derivative with a benzylsulfonyl group attached to the nitrogen atom of the piperazine ring

Biological activity

Studied for its potential as a serotonin receptor agonist

Therapeutic applications

Investigated for the treatment of various medical conditions, including depression, anxiety, and other central nervous system disorders

Synthesis utility

Used as a building block in the synthesis of other chemical compounds

Intermediate value

Its properties and structure make it a valuable intermediate in organic synthesis

Upstream product

• 110-85-0 piperazine 
• 1939-99-7 benzenesulfonyl chloride 
• 221289-96-9 tert-butyl 4-(benzylsulfonyl)piperazine-1-carboxylate 

Downstream Products

• 936098-16-7 methyl 3-(2-{[4-(benzylsulfonyl)piperazin-1-yl]methyl}-4-chlorophenyl)propanoate 
• 936098-17-8 ethyl 3-(2-{[4-(benzylsulfonyl)piperazin-1-yl]methyl}-4-chlorophenyl)propanoate 

Relevant academic research and scientific papers

Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase

Human tissue transglutaminase (hTG2) is a multifunctional enzyme. It is primarily known for its calcium-dependent transamidation activity that leads to formation of an isopeptide bond between glutamine and lysine residues found on the surface of proteins, but it is also a GTP binding protein. Overexpression and unregulated hTG2 activity have been associated with numerous human diseases, including cancer stem cell survival and metastatic phenotype. Herein, we present a series of targeted covalent inhibitors (TCIs) based on our previously reported Cbz-Lys scaffold. From this structure-activity relationship (SAR) study, novel irreversible inhibitors were identified that block the transamidation activity of hTG2 and allosterically abolish its GTP binding ability with a high degree of selectivity and efficiency (kinact/KI > 105 M-1 min-1). One optimized inhibitor (VA4) was also shown to inhibit epidermal cancer stem cell invasion with an EC50 of 3.9 μM, representing a significant improvement over our previously reported "hit" NC9.

Novel Compounds

The invention relates to substituted aryl acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa

The present application describes inhibitors of factor Xa of formula I: or pharmaceutically acceptable salt forms thereof, wherein W, W1, W2, and W3may be N or C and J, Ja, and Jbcombine to form a substituted carbocycle or heterocycle.